Q-omics provides the consensus-scored DCAF8 profile across patient tissues and cancer cell-line models. DCAF8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DCAF8 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, DCAF8 protein abundance shows 22,489 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KICH, and GBM as cancer lineages where DCAF8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF8 survival associations across molecular data types. DCAF8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF8 RNA expression–survival associations across cancer types. High DCAF8 expression shows unfavorable associations in ACC, COAD, UVM and UCEC, but favorable associations in HNSC and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DCAF8 RNA expression.
This table summarizes DCAF8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAF8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF8 shows lower tumor expression in KICH, UCEC and LUAD and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher DCAF8 RNA expression in normal versus tumor tissue (log2 FC = −1.173, t-test p < 0.001).
This table shows molecular features associated with DCAF8 in patient tissues and cancer cell lines. In patient samples, DCAF8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
